culty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form
10-Q, and any subsequent SEC filings.
Source: Forest Laboratories, Inc.
1. Corey R, Wilcox M, Talbot GH, et al. CANVAS-1: Randomized,
Double-blinded, Phase 3 Study (P903-06) of the Efficacy and Safety of
Ceftaroline vs. Vancomycin plus Aztreonam in Complicated Skin and Skin
Structure Infections (cSSSI). To be presented at ICAAC / IDSA 2008.
2. Jones RN, Fritsche TR, Sader HS. Ceftaroline activity tested against
organisms causing skin and skin structure infections (SSSIs) isolated in
USA and European medical centers in 2008 (Poster C1-160). To be presented
at ICAAC / IDSA 2008.
3. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of
ceftaroline tested against contemporary (2008) bacteria isolated from
community-acquired respiratory tract infections (CARTI), including
oxacillin-resistant S. aureus (MRSA) (Poster C2-1974).To be presented at
ICAAC / IDSA 2008.
4. Patel SN, McGeer A, Green K,et al. Activities of cethromycin (CETH),
ceftaroline (CPT), and ceftobiprole (BPR) against multi-drug resistant
(MDR) Streptococcus pneumoniae (SP) isolates from Canadian Bacterial
Surveillance Network (CBSN) (Poster C1-3843). To be presented at ICAAC /
5. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline
(CPT) vs. vancomycin (VM) against MRSA and hVISA strains in a
pharmacokinetic/pharmacodynamic (PK/PD) model (Poster A-979). To be
presented at ICAAC / IDSA 2008.
6. Saravolatz LD, Pawlak J, Johnson L. In vitro activity of ceftaroline
against CA-MRSA, VISA, VRSA and daptomycin-non-susceptible Staphylococcus
aureus (DNSSA) (Poster C1-162). To be presented at ICAAC / IDSA 200
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
|SOURCE Forest Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer2
. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer3
. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society4
. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure5
. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board6
. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board7
. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures8
. Kuvan Receives Positive Opinion From CHMP for European Approval9
. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results10
. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation11
. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model